Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women

Diabetes

Volumn 59, Issue 5, 2010, Pages 1153-1160

  Mora, Samia ^a   Otvos, James D ^b   Rosenson, Robert S ^c   Pradhan, Aruna ^a,d   Buring, Julie E ^a,e   Ridker, Paul M ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LIPOSCIENCE INC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; EDUCATION; EXERCISE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MOLECULAR WEIGHT; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 77951832314     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1114     Document Type: Article

References (26)

1. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
2. Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1998;9:211-219 (Pubitemid 28274350)
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
4. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-1379
5. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48:171-180 (Pubitemid 34272531)
6. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-1180 (Pubitemid 34764870)
7. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-870 (Pubitemid 44716510)
8. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002;90:22i-29i
9. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462 (Pubitemid 36173203)
10. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations: results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54: 264-270
11. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55 (Pubitemid 41002838)
12. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65 (Pubitemid 41002839)
13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
14. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005;111:3465-3472 (Pubitemid 40923401)
15. Liu S, Lee IM, Song Y, Van Denburgh M, Cook NR, Manson JE, Buring JE. Vitamin E and risk of type 2 diabetes in the Women's Health Study randomized controlled trial. Diabetes 2006;55:2856-2862 (Pubitemid 44923687)
16. Pradhan AD, Cook NR, Manson JE, Ridker PM, Buring JE. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 2009;32:3-8
17. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197 (Pubitemid 27274286)
18. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 2004;27: 9-12 (Pubitemid 38196701)
19. Hainline A, Karon J, Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. Bethesda, MD, U.S. Dept of Health and Human Services, 1982
20. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Saad MF, Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211-217
21. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-316 (Pubitemid 47080485)
22. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001
23. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-939
24. Wilson PWF, Meigs J. Risk of type 2 diabetes mellitus and coronary heart disease: a pivotal role for metabolic factors. Eur Heart J Supplements 2008;10:B11-B15
25. Tilly-Kiesi M, Knudsen P, Groop L, Taskinen MR. Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose-tolerant relatives of NIDDM patients: Botnia Study Group. J Lipid Res 1996;37:1569-1578 (Pubitemid 26249986)
26. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-1236